Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.72 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.71 |
| ▸ | AHR | P35869 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14310714 | 0.89 | EGFR (0.72) | EGFRERBB2AHR | |
| SCHEMBL30513 | 0.84 | EGFR (1.00) | EGFRERBB2AHR | |
| SCHEMBL29690398 | 0.84 | EGFR (1.00) | EGFRERBB2AHR | |
| SCHEMBL159209 | 0.83 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL1262804 | 0.83 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL29350058 | 0.83 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL31060510 | 0.83 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL14578431 | 0.83 | EGFR (0.72) | EGFRERBB2AHR | |
| SCHEMBL4586872 | 0.83 | EGFR (0.80) | EGFRERBB2AHR | |
| SCHEMBL31060998 | 0.83 | EGFR (1.00) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
| US-7879861-B2 | 4-N-(3-bromophenyl)-6-N-(2-chloroethyl)quinazoline-4,6-diamine, capable of both inhibiting epidermal growth factor receptors and damaging DNA; antitumor and antiproliferative agents | MCGILL UNIVERSITY (CA) | 2011-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | EGFR 48/4885ERBB2 7/4885AHR 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.